<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005160.pub2" GROUP_ID="LIVER" ID="170704011912173369" MERGED_FROM="" MODIFIED="2008-10-16 18:49:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:54 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-10-16 18:49:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis</TITLE>
<CONTACT>
<PERSON ID="19558" MODIFIED="2008-10-16 17:42:15 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rocco</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Orlando</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>rocco.orlando@unipd.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical and Surgical Sciences</DEPARTMENT>
<ORGANISATION>University of Padua Medical School</ORGANISATION>
<ADDRESS_1>via Giustiani, 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Padova</CITY>
<ZIP>35128</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 049 821 3293</PHONE_1>
<PHONE_2/>
<FAX_1>+39 049 8212151</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-10-16 17:42:11 +0100" MODIFIED_BY="dimitrinka nikolova">
<PERSON ID="19558" MODIFIED="2008-10-16 17:42:04 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rocco</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Orlando</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>rocco.orlando@unipd.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical and Surgical Sciences</DEPARTMENT>
<ORGANISATION>University of Padua Medical School</ORGANISATION>
<ADDRESS_1>via Giustiani, 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Padova</CITY>
<ZIP>35128</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 049 821 3293</PHONE_1>
<PHONE_2/>
<FAX_1>+39 049 8212151</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8FD5061A82E26AA20088EE030D7FADCA" MODIFIED="2008-10-16 17:42:06 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Lorenzo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Azzalini</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>azzalini@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Servei de Cardiologia</DEPARTMENT>
<ORGANISATION>Hospital de la Santa Creu i Sant Pau</ORGANISATION>
<ADDRESS_1>Sant Antoni María Claret 167</ADDRESS_1>
<ADDRESS_2/>
<CITY>Barcelona</CITY>
<ZIP>08025</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34935565945</PHONE_1>
<PHONE_2/>
<FAX_1>+34935565603</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19557" MODIFIED="2008-10-16 17:42:09 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Serena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Orando</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>serena.orando@libero.it, piediblu@libero.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Instituto di Anestesia e Rianimazione</DEPARTMENT>
<ORGANISATION>Universitá Degli Studi di Firenze</ORGANISATION>
<ADDRESS_1>Azienda Ospedaliero-Universitaria di Careggi</ADDRESS_1>
<ADDRESS_2>Viale della Maternitá</ADDRESS_2>
<CITY>Firenze</CITY>
<ZIP>50134</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19556" MODIFIED="2008-10-16 17:42:11 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Flavio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lirussi</LAST_NAME>
<SUFFIX>M.D., Ph.D.</SUFFIX>
<POSITION/>
<EMAIL_1>fli@ihd.euro.who.int</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Scientist, Socioeconomic Determinants of NCDs</DEPARTMENT>
<ORGANISATION>WHO Regional Office for Europe, European Office for Investment for Health and Development</ORGANISATION>
<ADDRESS_1>Campo Santo Stefano, San Marco 2847</ADDRESS_1>
<ADDRESS_2/>
<CITY>Venice</CITY>
<ZIP>I-30124</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 041 279 3865</PHONE_1>
<PHONE_2>+39 041 279 3841</PHONE_2>
<FAX_1>+39 041 279 3869</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-16 18:49:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Minor update: 19/02/07&lt;/p&gt;&lt;p&gt;New studies sought but none found: 26/06/06&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:42:33 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova">
<UP_TO_DATE>
<DATE DAY="21" MONTH="9" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="6" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="9" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="16" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-16 17:42:23 +0100" MODIFIED_BY="dimitrinka nikolova"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUMMARY>
<TITLE>No evidence to support or refute the effect of bile acids in patients with non-alcoholic fatty liver disease and/or steatohepatitis</TITLE>
<SUMMARY_BODY>
<P>Non-alcoholic fatty liver disease is a condition characterised by fatty deposition in the hepatocytes in patients with minimal or no alcohol intake. Hepatic injury might be improved by bile acids. This systematic review identified four randomised clinical trials. Bile acids did not cause any liver-related deaths and were associated with only minor, non-specific adverse events. However, these agents did not show any significant amelioration of common liver function tests as compared with placebo. Moreover, data on the radiological (ultrasonography and computer tomography scan) and/or histological response were too limited to draw any conclusions. Further randomised placebo-controlled trials are necessary. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Non-alcoholic fatty liver disease is a condition characterised by fatty deposition in the hepatocytes of patients with minimal or no alcohol intake. Some patients develop non-alcoholic steatohepatitis. Bile acids may potentially protect cellular structures and may be of benefit in patients with non-alcoholic fatty liver or steatohepatitis.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To systematically evaluate the beneficial and harmful effects of bile acids versus no intervention, placebo, or other interventions for patients with non-alcoholic fatty liver or steatohepatitis. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I> (July 2005), the <I>Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) in <I>The Cochrane Library</I> (Issue 2, 2005), <I>MEDLINE</I> (1966 to July 2005), <I>EMBASE</I> (1980 to July 2005), and the<I> Chinese Biomedical Database</I> (1978 to July 2005). No language restrictions were applied.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials evaluating any bile acids versus no intervention, placebo, or other interventions in patients with NAFLD. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We extracted data from the identified trials as well as contacted authors. We evaluated the methodological quality of the randomised trials by assessing the generation of allocation sequence, allocation concealment, blinding, and follow-up. We made our analyses following the intention-to-treat method by imputing missing data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We identified four randomised clinical trials randomising 279 patients. Only one of the trials was considered a low-bias risk trial. One of the trials reported a non-liver-related death in the bile acid group. No significant differences were found regarding mortality or improvement in liver function tests observed after treatment with ursodeoxycholic acid. Data on the radiological and histological responses were too scant to draw any definite conclusions. Adverse events were non-specific and considered of no major clinical relevance.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Presently, there are insufficient data to support or refute the use of ursodeoxycholic acid for patients with non-alcoholic fatty liver or steatohepatitis. It may be advisable to carry out large randomised clinical trials on this topic.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova">
<BACKGROUND MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Non-alcoholic fatty liver disease (NAFLD) is a clinical-pathological condition encompassing a spectrum of liver injury, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis (<LINK REF="REF-Brunt-2001" TYPE="REFERENCE">Brunt 2001</LINK>; <LINK REF="REF-Angulo-2002a" TYPE="REFERENCE">Angulo 2002a</LINK>; <LINK REF="REF-Angulo-2002b" TYPE="REFERENCE">Angulo 2002b</LINK>; <LINK REF="REF-Grant-2004" TYPE="REFERENCE">Grant 2004</LINK>; <LINK REF="REF-Harrison-2004" TYPE="REFERENCE">Harrison 2004</LINK>). NAFLD is characterised by fatty deposition in the liver cells and occurs in patients with little or no history of alcohol intake, but with insulin resistance (or metabolic) syndrome and is particularly associated with obesity (<LINK REF="REF-Festi-2004" TYPE="REFERENCE">Festi 2004</LINK>), type 2 diabetes mellitus, and hyperlipidaemia (<LINK REF="REF-Reid-2001" TYPE="REFERENCE">Reid 2001</LINK>; <LINK REF="REF-Angulo-2002a" TYPE="REFERENCE">Angulo 2002a</LINK>; <LINK REF="REF-Chitturi-2002" TYPE="REFERENCE">Chitturi 2002</LINK>; <LINK REF="REF-Harrison-2004" TYPE="REFERENCE">Harrison 2004</LINK>). Its prevalence is increasing in high-income countries, being now recognised as the most common liver disease in the United States and spreading rapidly to the Asian-Pacific region (<LINK REF="REF-McCullough-2002" TYPE="REFERENCE">McCullough 2002</LINK>; <LINK REF="REF-Farrell-2003" TYPE="REFERENCE">Farrell 2003</LINK>; <LINK REF="REF-Clark-2006" TYPE="REFERENCE">Clark 2006</LINK>). While hepatic steatosis has a benign clinical course, NASH may progress to cirrhosis (in up to 20% of patients), liver failure, and even hepatocellular carcinoma (<LINK REF="REF-Reid-2001" TYPE="REFERENCE">Reid 2001</LINK>; <LINK REF="REF-Bugianesi-2002" TYPE="REFERENCE">Bugianesi 2002</LINK>; <LINK REF="REF-McCullough-2002" TYPE="REFERENCE">McCullough 2002</LINK>). Moreover, it remains unclear why only 15% to 20% of patients with NAFLD develop NASH (<LINK REF="REF-McCullough-2002" TYPE="REFERENCE">McCullough 2002</LINK>; <LINK REF="REF-Festi-2004" TYPE="REFERENCE">Festi 2004</LINK>; <LINK REF="REF-Grant-2004" TYPE="REFERENCE">Grant 2004</LINK>).</P>
<P>The pathophysiology of NAFLD is not clear. Current evidence suggests that insulin resistance and lipid peroxidation play a role in the pathogenesis of this condition. Insulin resistance results in important changes in lipid metabolism, which include enhanced peripheral lipolysis, increased triglycerides synthesis, and increased hepatic uptake of fatty acids. Free fatty acids induce several P-450 microsomal lipoxygenases, which produce hepatotoxic free reactive oxygen species with resultant steatohepatitis. Lipid peroxidation and reactive oxygen species can deplete antioxidant enzymes, thus rendering the liver more susceptible to oxidative stress (<LINK REF="REF-Kumar-2001" TYPE="REFERENCE">Kumar 2001</LINK>; <LINK REF="REF-Reid-2001" TYPE="REFERENCE">Reid 2001</LINK>; <LINK REF="REF-Oneta-2002" TYPE="REFERENCE">Oneta 2002</LINK>; <LINK REF="REF-Festi-2004" TYPE="REFERENCE">Festi 2004</LINK>; <LINK REF="REF-Friis_x002d_Liby-2004" TYPE="REFERENCE">Friis-Liby 2004</LINK>; <LINK REF="REF-Grant-2004" TYPE="REFERENCE">Grant 2004</LINK>; <LINK REF="REF-Videla-2004" TYPE="REFERENCE">Videla 2004</LINK>). Ursodeoxycholic acid (UDCA) might prevent steatosis by protecting against mitochondrial injury, by inducing a plasma membrane stabilising effect, and by decreasing lipid peroxidation. Moreover, taurine conjugated bile acids could inhibit the activity of some microsomal enzymes, such as CYP2E1, which in turn are induced by free fatty acids (<LINK REF="REF-Chang-2006" TYPE="REFERENCE">Chang 2006</LINK>).</P>
<P>UDCA inhibits the activation of Kupffer cells caused by toxic bile salts and thus acts as an antioxidant agent (<LINK REF="REF-Sokol-1993" TYPE="REFERENCE">Sokol 1993</LINK>). Furthermore, UDCA increases hepatocyte levels of glutathione and thio-containing protein, therefore protecting hepatocytes against oxidative injury. The drug may alter intestinal absorption or eliminate toxic hydrophobic bile acids from the liver or reduce the toxic effects of these hydrophobic compounds on cellular or subcellular membranes of hepatocytes. UDCA may also reduce the expression of class II HLA inhibitors, the production of interleukin and interferon, thus acting as an immunomodulator. In addition, UDCA seems to reduce reactive oxygen species (<LINK REF="REF-Laurin-1996a" TYPE="REFERENCE">Laurin 1996a</LINK>; <LINK REF="REF-Trauner-1999" TYPE="REFERENCE">Trauner 1999</LINK>; <LINK REF="REF-Lazaridis-2001" TYPE="REFERENCE">Lazaridis 2001</LINK>; <LINK REF="REF-Oneta-2002" TYPE="REFERENCE">Oneta 2002</LINK>; <LINK REF="REF-Paumgartner-2002" TYPE="REFERENCE">Paumgartner 2002</LINK>). Bile acids are hepatotoxic when administered to cultured hepatocytes due to the fact that these agents interact with biomembranes with resultant necrosis and/or apoptosis. By contrast, the hydrophilic bile acid UDCA protects hepatocytes and bile duct epithelial cells against necrosis and apoptosis induced by more hydrophobic bile acids (<LINK REF="REF-Trauner-1999" TYPE="REFERENCE">Trauner 1999</LINK>).</P>
<P>There is no proven effective therapy for NAFLD (<LINK REF="REF-Angelico-2007" TYPE="REFERENCE">Angelico 2007</LINK>; <LINK REF="REF-Lirussi-2007" TYPE="REFERENCE">Lirussi 2007</LINK>). Treatment has focused on the management of overweight, diabetes, and hyperlipidaemia (<LINK REF="REF-Dixon-2004" TYPE="REFERENCE">Dixon 2004</LINK>). Results of pilot or uncontrolled studies evaluating clofibrate, gemfibrozil, atorvastatin, metformin, thiazolidinedione derivatives, and antioxidants such as vitamin E, betaine, and N-acetylcysteine suggest that these medications may be of potential benefit (<LINK REF="REF-Angulo-2002b" TYPE="REFERENCE">Angulo 2002b</LINK>; <LINK REF="REF-Younossi-2002" TYPE="REFERENCE">Younossi 2002</LINK>; <LINK REF="REF-Wang-2002" TYPE="REFERENCE">Wang 2002</LINK>; <LINK REF="REF-Neuschwander_x002d_T-2003" TYPE="REFERENCE">Neuschwander-T 2003</LINK>). However, these agents need first to be tested in adequately conducted randomised clinical trials with clinically relevant outcome measures and extended follow-up (<LINK REF="REF-Angelico-2007" TYPE="REFERENCE">Angelico 2007</LINK>).</P>
<P>Based on current knowledge of the pathogenetic mechanisms involved in NAFLD and NASH, UDCA or other bile acids could be beneficial in this condition. However, we could not find any systematic reviews or meta-analyses addressing the effect of UDCA or other bile acids for patients with NAFLD or NASH.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the beneficial and harmful effects of bile acids for non-alcoholic fatty liver disease or steatohepatitis (NAFLD or NASH).</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-16 17:44:52 +0100" MODIFIED_BY="dimitrinka nikolova">
<SELECTION_CRITERIA MODIFIED="2008-10-16 17:44:52 +0100" MODIFIED_BY="dimitrinka nikolova">
<CRIT_STUDIES>
<P>All randomised clinical trials, regardless of publication status, number of patients randomised, language or blinding.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-16 17:44:52 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Participants of any age, sex, or ethnic origin with NAFLD, including NASH and/or cryptogenic cirrhosis diagnosed on the basis of the following criteria:<BR/>(1) Imaging techniques showing evidence of hepatic steatosis, and/or liver biopsy showing histological alterations including simple steatosis, fatty infiltration plus nonspecific inflammation, steatohepatitis, fibrosis, or cirrhosis.<BR/>(2) Daily alcohol intake less than 20 g in women and 40 g in men (<LINK REF="REF-Becker-1996" TYPE="REFERENCE">Becker 1996</LINK>; <LINK REF="REF-Neuschwander_x002d_T-2003" TYPE="REFERENCE">Neuschwander-T 2003</LINK>).<BR/>(3) Liver biopsy evidence (when available) of histologic damage including simple steatosis, fatty infiltration plus nonspecific inflammation, steatohepatitis, fibrosis, and cirrhosis.</P>
<P>We excluded trials enrolling patients with other causes of hepatic steatosis or steatofibrosis including hepatitis B, hepatitis C, autoimmune hepatitis, and genetic liver disease such as Wilson's disease and haemochromatosis. Trials considering patients with one or more causes commonly associated with secondary NAFLD (drugs, surgical procedures, and miscellaneous disorders such as a- or hypo-betalipoproteinaemia, partial lipodystrophy, environmental toxins, or total parenteral nutrition) were also excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Bile acids (UDCA, tauro-ursodeoxycholic acid, chenodeoxycholic acid, and other bile acids that we might identify) administered at any dose, duration, and route of administration, given separately or in combination versus no intervention, placebo, or other interventions. Co-interventions were allowed if used equally in the intervention groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-16 17:44:52 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>
<B>Primary outcome measures</B>
<BR/>(1) All-cause mortality: number of deaths irrespective of cause.<BR/>(2) Liver-related mortality.<BR/>(3) Liver-related complications including hepatocellular carcinoma and decompensated liver disease.<BR/>(4) Radiological response (degree of fatty liver infiltration assessed by ultrasound, computer tomography scanning, or nuclear magnetic resonance) and/or histological response (number of patients with histological improvement/deterioration and changes in the degree of fatty liver infiltration, inflammation, and fibrosis) based on the Brunt system or its modifications (<LINK REF="REF-Brunt-2001" TYPE="REFERENCE">Brunt 2001</LINK>; <LINK REF="REF-Harrison-2003" TYPE="REFERENCE">Harrison 2003</LINK>).<BR/>(5) Histological response (number of patients with histological improvement/deterioration and changes in the degree of fatty liver infiltration, inflammation, and fibrosis).</P>
<P>
<B>Secondary outcome measures</B>
<BR/>(6) Biochemical response (serum activities of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatases, gamma-glutamyl-transpeptidase, total bilirubin, and ferritin).<BR/>(7) Adverse events (any adverse events as reported in trials). Depending on the availability of data, we attempted to classify adverse events as serious or non-serious. Serious adverse events were defined as any outward medical occurrence that was life threatening, resulted in death or persistent or significant disability, or any medical event which may have jeopardised the patient or required intervention to prevent it. All other adverse events (ie, any medical occurrence not necessarily having a casual relationship with the treatment, but did, however, cause a dose reduction or discontinuation of treatment) were considered non-serious.<BR/>(8) Quality-of-life measures.<BR/>(9) Cost effectiveness.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-16 17:44:37 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(July 2006), the<I> Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>)<I> </I>in <I>The Cochrane Library </I>(Issue 2, 2006), <I>MEDLINE</I> (1950 to July 2006), <I>EMBASE</I> (1980 to July 2006), and the <I>Chinese Biomedical Database</I> (1978 to July 2005). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the search strategy we applied to the individual databases.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-16 17:42:49 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>
<B>Trial selection</B>
<BR/>Two authors (FL and LA) independently assessed if the identified trials fulfilled the inclusion criteria. Excluded trials were listed in 'Characteristics of excluded studies' and reasons for exclusion were given.</P>
<P>
<B>Data extraction<BR/>
</B>LA extracted data and RO validated the data extraction. We also wrote to several authors of included trials asking them to specify the data of interest that were not clearly reported in their studies.<BR/>
</P>
<UL>
<LI>Trial characteristics: date, location and funding of the trial, length of follow-up, use of intention-to-treat analyses, as well as the publication status.</LI>
<LI>Patient characteristics: number of patients randomised, inclusion and exclusion criteria, mean (or median) age, sex ratio.</LI>
<LI>Intervention characteristics: dose, duration and mode of administration of various bile acids and/or of additional intervention(s).</LI>
<LI>Outcome measures: number of events in the intervention group and in the control group.</LI>
</UL>
<P>
<BR/>
<B>Methodological quality</B>
<BR/>We assessed the methodological quality of the randomised clinical trials by the following components: generation of the allocation sequence, allocation concealment, double-blinding, and follow-up (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>).</P>
<P>
<B>
<I>Generation of the allocation sequence</I>
</B>
<BR/>
</P>
<UL>
<LI>Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice will be considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.</LI>
<LI>Inadequate, if a system involving dates, names, or admittance numbers were used for the allocation of patients. These studies are known as quasi-randomised and were excluded from the present review when assessing beneficial effects.</LI>
</UL>
<P>
<BR/>
<B>
<I>Allocation concealment </I>
</B>
<BR/>
</P>
<UL>
<LI>Adequate, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.</LI>
<LI>Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</UL>
<P>
<BR/>
<B>
<I>Blinding (or masking)</I>
</B>
<BR/>
</P>
<UL>
<LI>Adequate, if the trial was described as double blind and the method of blinding involved identical placebo or active drugs.</LI>
<LI>Unclear, if the trial was described as double blind, but the method of blinding was not described.</LI>
<LI>Not performed, if the trial was not double blind.</LI>
</UL>
<P>
<BR/>
<B>
<I>Follow-up</I>
</B>
<BR/>
</P>
<UL>
<LI>Adequate, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.</LI>
<LI>Unclear, if the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.</LI>
<LI>Inadequate, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>
<BR/>Furthermore, we have registered whether or not the randomised clinical trials have used an intention-to-treat analysis (<LINK REF="REF-Gluud-2001" TYPE="REFERENCE">Gluud 2001</LINK>) and sample size calculation.</P>
<P>In case that data have not been reported sufficiently or are not published at all, we have sought further information by correspondence with the authors.</P>
<P>
<B>Statistical methods<BR/>
</B>We performed the meta-analyses according to the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). We used the software package (RevMan 4.2) provided by The Cochrane Collaboration. For dichotomous variables, we calculated the relative risks with 95% confidence interval and continuous outcome measures as weighted mean differences (WMD) with 95% CI. We used a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and a fixed-effect model (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>), with the significant level set at P = 0.05. In case of discrepancy between the two models we reported both results, otherwise we reported only the results from the fixed-effect model. We performed subgroup analyses depending on the methodological quality of the trials in order to compare the intervention effect in trials with adequate methodological quality to that of trials with unclear or inadequate methodological quality. Heterogeneity was explored by chi-squared test with significance set at P value <U>&lt;</U> 0.10 and the quantity of heterogeneity was measured by I<SUP>2</SUP> (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). Regarding the primary outcome measures, we included patients with incomplete or missing data in the sensitivity analyses by imputing them (<LINK REF="REF-Hollis-1999" TYPE="REFERENCE">Hollis 1999</LINK>). This kind of approach, as part of sensitivity analyses, allowed us to evaluate the robustness of the findings of a meta-analysis as follows:<BR/>
</P>
<UL>
<LI>Available case analysis: data on only those whose results are known, using as denominator the total number of patients who completed the trial;</LI>
<LI>Assuming poor outcome: dropouts from both the bile acids and control groups had the primary outcomes;</LI>
<LI>Assuming good outcome: none of the dropouts from the bile acids and control groups had the primary outcomes;</LI>
<LI>Extreme case favouring bile acids: none of the dropouts from the bile acids group but the dropouts from the control group had the primary outcomes;</LI>
<LI>Extreme case favouring control: all dropouts from the bile acids group but none from the control group had the primary outcomes.</LI>
</UL>
<P>For the secondary outcomes, we adopted 'available case analysis'.</P>
<P>The analyses included all patients irrespective of compliance or follow-up following the 'intention-to-treat' principle and using the last reported observed response ('carry forward'). We planned to use funnel plot asymmetry to assess the existence of bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDY_DESCRIPTION MODIFIED="2008-10-16 17:44:52 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>
<B>Search results</B>
<BR/>
<I>MEDLINE</I> via <I>PubMed</I> identified 62 references. Of these, 53 were clearly irrelevant to this review and were excluded on the basis of their titles and abstracts. Of the remaining nine references five were excluded (see Table of excluded studies). <I>EMBASE</I> identified 99 references. Of these, 92 were clearly irrelevant to this review and were excluded on the basis of their titles and abstracts. Of the remaining seven references, two were included in the review, four were excluded (see Table of excluded studies), and one is still waiting assessment because we have not yet obtained the paper publication. <I>The Cochrane Hepato-Biliary Controlled Trials Register</I> identified five references, all of which were protocols of ongoing studies. The <I>Cochrane Central Register of Controlled Trials </I>in <I>The Cochrane Library</I> identified 146 references, 143 of which were clearly irrelevant to this review, whereas two were relevant, but not present in either <I>MEDLINE</I> via <I>PubMed</I> or <I>EMBASE</I>, and one had already been identified in both these databases. <I>The</I> <I>Chinese Biomedical Database</I> did not provide any valid reference. Three more references were obtained by reading the pertinent literature.</P>
<P>
<B>Included trials</B>
<BR/>Four randomised clinical trials evaluating UDCA were included. The included trials differed markedly in their inclusion criteria: two (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>) assessed hepatic steatosis by means of ultrasonography, whereas the other two (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>) diagnosed NASH/NAFLD by means of histology. Moreover, in one trial (<LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>) the included patients were all women, whereas the remaining three trials enrolled both sexes. In three trials, one of the inclusion criteria was increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>). Major exclusion criteria were other causes of chronic liver disease (hepatitis B and/or C, haemochromatosis, &#945;<SUB>1</SUB>-antitrypsin deficiency, Wilson's disease, or autoimmune liver disease), use of drugs associated with the development of NASH, and alcohol abuse. The threshold for alcohol abuse was defined in three trials (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>): less than 40 g/week in the first two trials, less than 20 g/day in the third one. All the included trials used UDCA, given at different dosages, either alone (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>), or in combination with a low-calorie diet (<LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>), or preceded by a weight-reducing diet (<LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>). UDCA was given at a daily dose of 10 to 15 mg/kg (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>) or administered at a fixed dosage of 1200 mg/day (<LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>). The intervention in the control group was placebo in three trials while the Turkish trial (<LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>) used a combination of vitamin C and E. The duration of treatment was variable, ranging from six weeks (<LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>) to two years (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>).</P>
<P>
<B>Excluded studies</B>
<BR/>A total of eight studies were excluded for the reasons given in the Table of excluded studies. One of them (<LINK REF="STD-Bernal_x002d_Reyes-2002" TYPE="STUDY">Bernal-Reyes 2002</LINK>) was an uncontrolled and non-randomised study, which compared the use of UDCA and &#945;-tocopherol in patients with NASH. The study by Cicek et al (<LINK REF="STD-Cicek-2004" TYPE="STUDY">Cicek 2004</LINK>), which was published as an abstract, compared UDCA and gemfibrozil in patients with NASH; its methodology was unclear. Similarly, another two studies (<LINK REF="STD-Guma-1997" TYPE="STUDY">Guma 1997</LINK>; <LINK REF="STD-Ceriani-1998" TYPE="STUDY">Ceriani 1998</LINK>), also published in an abstract form, compared the use of UDCA with a low-fat diet in patients with NASH, but their methodology was unclear. The study by Tuncer et al (<LINK REF="STD-Tuncer-2003" TYPE="STUDY">Tuncer 2003</LINK>) investigated, in patients with NAFLD, the effects of pentoxifylline versus UDCA on a number of cytokines, which were not included in the types of outcome measures of our review. One study (<LINK REF="REF-Laurin-1996a" TYPE="REFERENCE">Laurin 1996a</LINK>) was a pilot study, and another was an observational study (<LINK REF="STD-Vajro-2000" TYPE="STUDY">Vajro 2000</LINK>). The latter was excluded because its methodology was unclear. Finally, the study by Kiyici et al (<LINK REF="STD-Kiyici-2003" TYPE="STUDY">Kiyici 2003</LINK>) was excluded because it was a prospective study using atorvastatin in hyperlipidaemic NASH patients and UDCA in normolipidaemic NASH patients.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>None of the included trials reported power calculations to estimate sample size.</P>
<P>There was only one high-quality trial with low risk of bias (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>). Generation of allocation sequence was considered adequate in two trials (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>): it was computer-generated in the first and was performed by means of a table of random numbers in the second one. In the other two trials (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>), it was unclear. Allocation concealment was considered adequate only in the trial by Lindor et al (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>) since it was performed by the pharmacy in each of the 13 participating medical centres. In the remaining three trials (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>) it was unclear. Blinding was considered adequate in all the trials but in the Turkish one, which was an open-label trial (<LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>). Follow-up was considered adequate in all four trials.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-16 17:44:52 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>As we have no convincing evidence that vitamin C and E substantially affect the course of liver disease, apart from maybe increasing serum alanine aminotransferase activity (<LINK REF="REF-Lirussi-2007" TYPE="REFERENCE">Lirussi 2007</LINK>), we included the <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK> trial in our analysis as a 'no intervention in the control group' trial. In the future, when updating the review with new trials, we will analyse vitamin C or vitamin E trials separately.<BR/>
<B>
<BR/>All-cause mortality and liver-related mortality</B>
<BR/>The trial by Lindor et al (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>) randomised 174 patients, 40 of whom were withdrawn for various reasons, including one patient dying of myocardial infarction. It was not clear whether this death occurred in the experimental or the control group. No liver-related or unrelated fatalities occurred in the other three trials (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>).</P>
<P>
<B>Liver-related complications<I>
<BR/>
</I>
</B>None of the trials reported on liver-related complications.</P>
<P>
<B>Radiological response<BR/>
</B>Radiological response was assessed by means of computed tomography in one trial (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>) and by ultrasonography in two trials (<LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>). In the Brazilian trial (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>), hepatic density remained virtually unchanged in both groups throughout the study: +0.9 HU (SD 4.15) in the UDCA group, -0.5 HU (SD 5.05) in the control group. In the Turkish trial (<LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>), no change in US steatosis score was observed in either of the two groups. By contrast, in the Mexican trial (<LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>), US steatosis score was reduced by 1.30 (SD 0.67) points in the UDCA group, and by 1.10 (SD 0.76) in the control group, the overall effect favouring UDCA treatment, though not significantly so (P = 0.07). Considering now the three trials independently from the radiological procedures used to assess changes in fatty infiltration of the liver, SMD was -0.22 (95% CI -0.60 to 0.16), heterogeneity was high (I<SUP>2 </SUP>= 83.7%) and the overall results showed no significant differences between UDCA and placebo/no intervention.</P>
<P>
<B>Histological response</B>
<BR/>Histological response was assessed only by Lindor et al (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>) who evaluated the scores of steatosis, inflammation/necrosis, and fibrosis before and after treatment. None of these scores changed significantly in the placebo or in the UDCA group. In fact, WMDs were -0.10 (95% CI -0.30 to 0.10) for the steatosis score, 0.10 (95% CI -0.16 to 0.36) for the inflammation/necrosis score, and 0.00 (95% CI -0.28 to 0.28) for the fibrosis score. Since these scores are not continuous variables, we have also calculated the number of patients with improvement of each histological variable and confirm that UDCA treatment does not significantly affect any of these features (see Table of Comparison or Outcome).</P>
<P>
<B>Biochemical response<BR/>
</B>Biochemical response was assessed by serum activities of AST, ALT, alkaline phosphatases (ALP), gamma-glutamyltranspeptidase (GGT), and serum total bilirubin levels.</P>
<P>AST activity was evaluated in all included trials. However, standard deviations were reported only in three trials (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>). UDCA-treated patients showed a non-significant decrease in AST activity (WMD -2.32 IU/L, 95% CI -5.37 to 0.72) versus control-treated patients. Heterogeneity was high (I<SUP>2 </SUP>= 96.7).</P>
<P>ALT activity was evaluated in all four trials. There were no significant differences between UDCA and placebo treatment: WMD was -1.04 IU/L (95% CI -4.13 to 2.04).</P>
<P>ALP activity was evaluated in two trials (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>), showing no significant differences between the UDCA group and the placebo group (WMD -3.18 IU/L, 95% CI -17.86 to 11.51).</P>
<P>GGT activity was evaluated in two trials (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>). GGT decreased moderately and not significantly (P = 0.06) at the end of the treatment period: WMD was -17.91 IU/L ( 95% CI -36.54 to 0.72).</P>
<P>Serum total bilirubin levels were assessed only in the study by Lindor et al (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>), showing no significant difference between the two study groups: WMD 0.00 &#956;mol/L, 95% CI -0.14 to 0.14.</P>
<P>No trials investigated changes in ferritin levels following the administration of UDCA supplements, placebo, or in respect to other interventions.<B>
<BR/>
</B>
<BR/>
<B>Adverse events</B>
<BR/>Among the four trials, only two (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>) provided detailed information on adverse events. In <LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK> et al trial, forty patients did not complete the trial. Reasons for discontinuation were the following: seven patients were noncompliant, two patients were lost to follow-up, 10 patients withdrew for personal reasons, one patient died of myocardial infarction, and 20 patients dropped out from the trial for adverse events due to the medication (either UDCA or placebo). Among these, the only life-threatening event was cardiac arrest that occurred in one UDCA-treated patient and in two patients receiving placebo. The other reasons for withdrawal due to drug intolerance were regarded as non-serious and included gastrointestinal intolerance (7/80 participants in the UDCA group, 5/86 patients in the placebo group), and miscellaneous adverse events: rash (two in the UDCA group, one in the placebo group), paraesthesia (one in the UDCA group, none in the placebo group), and renal failure (none in the UDCA group, one in the placebo group). The second trial (<LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>) reported that 3/29 patients in the UDCA group experienced nausea, epigastric pain and diarrhea, whereas no adverse events were noted in the vitamin-treated group (0/28 participants). For comparison, these symptoms were grouped under the definition of gastrointestinal intolerance and were included in the meta-analysis of non-serious adverse events, assuming that vitamin treatment was equivalent to placebo treatment. None of the differences concerning either serious or non-serious adverse events resulted significant (Comparisons 05-01 and 05-02).</P>
<P>The trial by Mendez-Sanchez et al (<LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>) reported that three patients withdrew either voluntarily or after becoming pregnant. Finally, the trial by Santos et al (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>) provided information concerning only the experimental group, in which no adverse events were reported.</P>
<P>
<B>Quality-of-life measures and cost effectiveness</B>
<BR/>Quality of life measures and cost-effectiveness were not reported in any of the trials.</P>
<P>
<B>Bias exploration </B>
<BR/>Due to the limited number of randomised clinical trials, we did not perform funnel plot analysis.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We identified four randomised clinical trials assessing the effect of bile acids in patients with NAFLD, including NASH and/or cryptogenic cirrhosis. There was considerable heterogeneity among these trials in respect to inclusion criteria, sample size, duration of treatment, and methods of outcome assessment. All the identified randomised clinical trials used UDCA. In addition, the intervention in the control group of the trials differed: from placebo with or without a low-calorie diet (<LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK>; <LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK>) to antioxidants (vitamin C plus vitamin E) (<LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>). It can, therefore, be debated whether the latter trial should be included in our analysis as a trial with 'no intervention' in the control group. However, we decided to keep this trial in our analysis since we were unable to find dramatic effects of vitamin E in these patients (apart from a raise in alanine aminotransferase activity) (<LINK REF="REF-Lirussi-2007" TYPE="REFERENCE">Lirussi 2007</LINK>). This, of course, does not exclude that vitamin C may cause benefit or harm. In addition, the exclusion of this trial would not have dramatically affected the results. In future versions of our review, we will, however, analyse such trials separately.</P>
<P>In spite of this heterogeneity we think these four trials represent the best available evidence on the effect of bile acids for patients with NAFLD/NASH. We were unable to detect any significant beneficial effects on mortality, liver-related mortality, liver-related complications, and fatty infiltration. Only the trial by Lindor et al (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>) assessed the histological response. Changes in the degree of steatosis, inflammation, or fibrosis were not significantly different between the two intervention groups.</P>
<P>Biochemical response was evaluated by means of the serum activity of different hepatic enzymes and of total bilirubin. All four trials assessed the effect of UDCA on serum transaminase. UDCA-treated patients did not differ significantly from control patients regarding AST and ALT activity. ALP activity and serum total bilirubin were measured in two trials (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>), which showed no significant difference between the experimental group and the control group. Finally, GGT activity was analysed in two trials (<LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK>; <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK>). UDCA-treated patients seemed to have a tendency to get lower GGT activity compared with control-treated patients, but this tendency was not significant.</P>
<P>As regards adverse events, <LINK REF="STD-Lindor-2004" TYPE="STUDY">Lindor 2004</LINK> et al reported that 20 patients discontinued the trial because of adverse events due to the medication (11 in the UDCA group versus 9 in the placebo group). <LINK REF="STD-Ers_x00f6_z-2005" TYPE="STUDY">Ersöz 2005</LINK> et al also reported on non-serious adverse events. <LINK REF="STD-M_x00e8_ndez_x002d_Sanchez-2004" TYPE="STUDY">Mèndez-Sanchez 2004</LINK> et al and <LINK REF="STD-Santos-2003" TYPE="STUDY">Santos 2003</LINK> et al did not report on adverse events.</P>
<P>In conclusion, the results of the randomised clinical trials identified in this review do not allow us to provide evidence on the pros or cons of bile acids in NAFLD or NASH, due to the small number of identified trials, the markedly variable duration of treatment, and, in general, their low methodological quality. We were, therefore, surprised to find an ongoing trial (<LINK REF="REF-Dufour-2005" TYPE="REFERENCE">Dufour 2005</LINK>), which randomises UDCA-treated patients to vitamin E versus placebo. We do not understand why this trial was designed in such a way by the investigators and why the ethics committee has approved it.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The data currently available are not sufficient to support or refute bile acids for patients with NAFLD or NASH. Accordingly, we do not recommend bile acids for patients with NAFLD/NASH outside randomised clinical trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Absence of evidence is not evidence of absence of effect. Further randomised clinical trials are needed to establish the potential beneficial and harmful effects of bile acids for patients with NAFLD or NASH. In such trials, careful consideration of the inclusion criteria and of the outcome measures will be necessary. Moreover, randomised clinical trials with a large enough sample size and lasting for a longer period may be advisable. Such trials ought to be placebo controlled and to be reported according to the CONSORT guidelines (http://www.consort-statement.org). </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Dimitrinka Nikolova and Christian Gluud of The Cochrane Hepato-Biliary Group for their help in the development of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>R Orlando drafted the protocol and developed the search strategies for the review. L Azzalini analysed the included trials and performed data analyses. S Orando helped in retrieving data and tested the search strategies. F Lirussi revised the review. All authors contributed to the improvement of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-16 17:44:54 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ers_x00f6_z-2005" NAME="Ersöz 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ersöz G, Günsar F, Karasu Z, Akay S, Batur Y, Akarca US</AU>
<TI>Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment</TI>
<SO>Turkish Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>3</NO>
<PG>124-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindor-2004" NAME="Lindor 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindor KD, Kowdley KV, Heathcote EJ, Harrison MD, Jorgensen R, Angulo P, et al</AU>
<TI>Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>770-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00e8_ndez_x002d_Sanchez-2004" NAME="Mèndez-Sanchez 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mèndez-Sanchez N, Gonzalez V, Chavez-Tapia N, Ramos MH, Uribe M</AU>
<TI>Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial</TI>
<SO>Annals of Hepatology</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>3</NO>
<PG>108-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-2003" NAME="Santos 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santos VN, Lanzoni VP, Szejnfeld D, Shigueoka D, Parise ER</AU>
<TI>A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid</TI>
<SO>Brazilian Journal of Medical and Biological Research</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>6</NO>
<PG>723-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernal_x002d_Reyes-2002" NAME="Bernal-Reyes 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernal-Reyes R, Escudero RB</AU>
<TI>Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report</TI>
<SO>Revista de Gastroenterologia Mexicana</SO>
<YR>2002</YR>
<VL>67</VL>
<NO>2</NO>
<PG>70-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceriani-1998" NAME="Ceriani 1998" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ceriani R, Brunati S, Morini L, Sacchi E, Colombo G</AU>
<TI>Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis (abstract)</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>386A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cicek-2004" NAME="Cicek 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cicek B, Koksal A, Oguz D, Erden E, Sahin T</AU>
<TI>Ursodeoxycholic acid and gemfibrozil in the treatment of non-alcoholic steatohepatitis: a randomized controlled trial</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>169-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guma-1997" NAME="Guma 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guma C, Viola L, Thomé M, Galdame O, Alvarez E</AU>
<TI>Ursodeoxycholic acid in the tratment of non-alcoholic steatohepatitis: result of a prospective clinical controlled trial</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>4 part 2</NO>
<PG>387A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiyici-2003" NAME="Kiyici 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al</AU>
<TI>Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis</TI>
<SO>Canadian Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>12</NO>
<PG>713-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laurin-1996" NAME="Laurin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GG, Ludwig J, et al</AU>
<TI>Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>23</VL>
<PG>1464-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuncer-2003" NAME="Tuncer 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuncer I, Uygan I, Dulger H, Turkdogan K, Sekeroglu R, Kosem M</AU>
<TI>The comparative effects of pentoxifylline and ursodeoxycholic acid on IL-1beta, IL-6, IL-8 and TNF-alfa levels in non-alcoholic fatty liver</TI>
<SO>Eastern Journal of Medicine</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>2</NO>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vajro-2000" NAME="Vajro 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N</AU>
<TI>Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children</TI>
<SO>Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>136</VL>
<NO>6</NO>
<PG>711-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Holoman-2001" NAME="Holoman 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holoman J, Glasa J, Bednarova A, Misianik J, Galbavy S, Kazar J</AU>
<TI>Effect of therapy of ursodeoxycholic acid in patients with non-alcholic steatohepatitis. A pilot study</TI>
<SO>Ceska a Slovenska Gastroenterologie a Hepatologie</SO>
<YR>2001</YR>
<VL>55</VL>
<NO>4</NO>
<PG>131-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-16 17:44:54 +0100" MODIFIED_BY="dimitrinka nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-16 17:44:54 +0100" MODIFIED_BY="dimitrinka nikolova">
<REFERENCE ID="REF-Angelico-2007" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Angelico 2007" NOTES="&lt;p&gt;Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005166. DOI: 10.1002/14651858.CD005166.pub2&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:53 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="OTHER">
<AU>Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F</AU>
<TI>Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007, Issue 1. Art. No.: CD005166. DOI: 10.1002/14651858.CD005166.pub2</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Angulo-2002a" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Angulo 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Angulo P</AU>
<TI>Nonalcoholic fatty liver disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>1221-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Angulo-2002b" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Angulo 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Angulo P, Lindor KD</AU>
<TI>Treatment of non-alcoholic steatohepatitis</TI>
<SO>Best Practice &amp; Research Clinical Gastroenterology</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>5</NO>
<PG>797-810</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becker-1996" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Becker 1996" TYPE="JOURNAL_ARTICLE">
<AU>Becker U, Deis A, Sorensen TI, Gronbæk M, Borch-Johnsen K, Florvall Muller C, et al</AU>
<TI>Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>5</NO>
<PG>1025-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brunt-2001" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Brunt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brunt EM</AU>
<TI>Nonalcoholic steatohepatitis: definition and pathology</TI>
<SO>Seminars in Liver Diseases</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>3-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bugianesi-2002" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bugianesi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al</AU>
<TI>Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>123</VL>
<NO>1</NO>
<PG>134-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2006" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Chang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH</AU>
<TI>Therapy of NAFLD: antioxidants and cytoprotective agents</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>3 suppl 1</NO>
<PG>S51-S60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chitturi-2002" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Chitturi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chitturi S, Farrel G, Frost L, Kriketos A, Lin R, Fung C, et al</AU>
<TI>Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<PG>403-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-2006" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Clark 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clark JM</AU>
<TI>The epidemiology of nonalcoholic fatty liver disease in adults</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>3 Suppl 1</NO>
<PG>S5-S10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dixon-2004" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Dixon 2004" TYPE="JOURNAL_ARTICLE">
<AU>Dixon JB, Bhathal PS, Hughes NR, O'Brien PE</AU>
<TI>Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>1647-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dufour-2005" MODIFIED="2008-10-16 17:44:54 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Dufour 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dufour JF, Oneta C, Gonvers JJ, Bihl F, Cermy A, Cereda JM, et al</AU>
<TI>A 2-years multicenter randomized placebo-controlled study testing UDCA in combination with vitamin E to treat NASH</TI>
<SO>Journal of Hepatology</SO>
<YR>2005</YR>
<VL>12 Suppl 2</VL>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farrell-2003" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Farrell 2003" TYPE="JOURNAL_ARTICLE">
<AU>Farrell GC</AU>
<TI>Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>124-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Festi-2004" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Festi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G</AU>
<TI>Hepatic steatosis in obese patients: clinical aspects and prognostic significance</TI>
<SO>Obesity Reviews</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>1</NO>
<PG>27-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friis_x002d_Liby-2004" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Friis-Liby 2004" TYPE="JOURNAL_ARTICLE">
<AU>Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E</AU>
<TI>High prevalence of metabolic complications in patient with non-alcoholic fatty liver disease</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>9</NO>
<PG>864-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2001" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gluud 2001" NOTES="&lt;p&gt;(ENTERED MANUALLY)&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:53 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="BOOK_SECTION">
<AU>Gluud C</AU>
<TI>Alcoholic hepatitis: no glucocorticosteroids?</TI>
<SO>Steatohepatitis (NASH and ASH), Falk Symposium 121</SO>
<YR>2001</YR>
<PG>322-42</PG>
<ED>Leuschner U, James OFW, Dancygier H</ED>
<PB>Kluwer Academic Publishers</PB>
<CY>Dordrecht</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grant-2004" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Grant 2004" TYPE="JOURNAL_ARTICLE">
<AU>Grant LM, Lisker-Melman M</AU>
<TI>Nonalcoholic fatty liver disease</TI>
<SO>Annals of Hepatology</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>3</NO>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harrison-2003" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Harrison 2003" TYPE="JOURNAL_ARTICLE">
<AU>Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S</AU>
<TI>Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>11</NO>
<PG>2485-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harrison-2004" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Harrison 2004" TYPE="JOURNAL_ARTICLE">
<AU>Harrison SA, Neuschwander-Tetri BA</AU>
<TI>Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</TI>
<SO>Clinical Liver Disease</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>4</NO>
<PG>861-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Higgins 2006" NOTES="&lt;p&gt;Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley &amp;amp; Sons, Ltd.&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:53 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</TI>
<SO>The Cochrane Library, Issue 4, 2006</SO>
<PB>John Wiley &amp; sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollis-1999" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Hollis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hollis S, Campbell F</AU>
<TI>What is meant by intention to treat analysis? Survey of published randomised controlled trials</TI>
<SO>British Medical Journal</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>319</NO>
<PG>670-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kjaergard 2001" NOTES="&lt;p&gt;Journal-Article&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:53 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21587469"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2001" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kumar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kumar D, Tandon RK</AU>
<TI>Use of ursodeoxycholic acid in liver diseases</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>3-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laurin-1996a" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Laurin 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al</AU>
<TI>Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol induced steatohepatitis: a pilot study</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>6</NO>
<PG>1464-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lazaridis-2001" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Lazaridis 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lazaridis KN, Gores GJ, Lindor KD</AU>
<TI>Ursodeoxycholic acid mechanism of action and clinical use in hepatobiliary disorders</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>35</VL>
<NO>1</NO>
<PG>134-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lirussi-2007" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Lirussi 2007" NOTES="&lt;p&gt;Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD004996. DOI: 10.1002/14651858.CD004996.pub3&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:53 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="OTHER">
<AU>Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F</AU>
<TI>Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007, Issue 1. Art. No.: CD004996. DOI: 10.1002/14651858.CD004996.pub3</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCullough-2002" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="McCullough 2002" TYPE="JOURNAL_ARTICLE">
<AU>McCullough AJ</AU>
<TI>Update on nonalcoholic fatty liver disease</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>3</NO>
<PG>255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Moher 1998" NOTES="&lt;p&gt;(Downloaded from MEDLINE)&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:53 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98417104"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neuschwander_x002d_T-2003" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Neuschwander-T 2003" TYPE="JOURNAL_ARTICLE">
<AU>Neuschwander-Tetri BA, Caldwell ST</AU>
<TI>Nonalcoholic steatohepatitis: summary of an AASLD single topic conference</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>5</NO>
<PG>1202-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oneta-2002" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Oneta 2002" TYPE="JOURNAL_ARTICLE">
<AU>Oneta CM, Dufour JF</AU>
<TI>Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2002</YR>
<VL>132</VL>
<PG>493-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paumgartner-2002" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Paumgartner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Paumgartner G, Beuers U</AU>
<TI>Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>3</NO>
<PG>525-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2001" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Reid 2001" TYPE="JOURNAL_ARTICLE">
<AU>Reid AE</AU>
<TI>Nonalcoholic steatohepatitis</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>121</VL>
<PG>710-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Schulz 1995" NOTES="&lt;p&gt;META-ANALYSIS. JOURNAL-ARTICLE. (Downloaded from MEDLINE)&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:53 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95123716"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sokol-1993" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Sokol 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sokol RJ, Devereaux M, Khandwala R, O'Brien K</AU>
<TI>Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes</TI>
<SO>Hepatology</SO>
<YR>1993</YR>
<VL>17</VL>
<PG>869-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trauner-1999" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Trauner 1999" TYPE="JOURNAL_ARTICLE">
<AU>Trauner M, Graziadei IW</AU>
<TI>Review article: mechanism of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>8</NO>
<PG>979-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Videla-2004" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Videla 2004" TYPE="JOURNAL_ARTICLE">
<AU>Videla LA, Rodrigo R, Araya J, Poniachik J</AU>
<TI>Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease</TI>
<SO>Free Radical Biology and Medicine</SO>
<YR>2004</YR>
<VL>37</VL>
<NO>9</NO>
<PG>1499-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2002" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Wang 2002" NOTES="&lt;p&gt;Wang RT, Koretz RL, Yee HF. Weight reduction for non-alcoholic fatty liver. (Protocol) The Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003619. DOI: 10.1002/14651858.CD003619&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:44:53 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="OTHER">
<AU>Wang RT, Koretz RL, Yee HF</AU>
<TI>Weight reduction for non-alcoholic fatty liver</TI>
<SO>(Protocol) The Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003619. DOI: 10.1002/14651858.CD00361</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Younossi-2002" MODIFIED="2008-10-16 17:44:53 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Younossi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Younossi ZM, Diehl AM, Ong JP</AU>
<TI>Nonalcoholic fatty liver disease: an agenda for clinical research</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>4</NO>
<PG>746-52</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Ers_x00f6_z-2005">
<CHAR_METHODS>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: not performed.</P>
<P>Follow-up: adequate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>- histologically-proven NAFLD<BR/>- persistently elevated transaminase more than 1.2 times the upper limits, after a three-month weight-reducing diet.</P>
<P>Exclusion criteria:<BR/>- ethanol consumption &gt;20 g/day;<BR/>- treatment with any drugs<BR/>- any other liver diseases (hepatitis B and C, autoimmune hepatitis, Wilson's disease, haemochromatosis, alpha1-antitrypsin deficiency);<BR/>- severe comorbid medical conditions (severe cardial, pulmonary, renal or psychological problems)<BR/>- absence of consent in the participation in the trial.</P>
<P>Characteristics of included patients:<BR/>- median age = 47 years<BR/>- males = 59%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>UDCA 10 mg/kg/day <BR/>versus <BR/>vitamin E 600 IU daily + vitamin C 500 mg daily, for 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes:<BR/>- ALT, AST, ALP, GGT, triglycerides and cholesterol levels every 2 months;<BR/>- liver ultrasonography was performed at the beginning and at the end of the trial.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>We wrote to the authors, but we have not obtained a reply yet.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lindor-2004">
<CHAR_METHODS>
<P>Generation of allocation sequence: adequate, computer-generated randomisation sequence.</P>
<P>Allocation concealment: adequate, centralised and performed by the pharmacy in each centre stratified according to diabetes, obesity, and hypertriglyceridemiae.</P>
<P>Blinding: adequate, placebo-controlled, double blinding.</P>
<P>Follow-up: adequate.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>- elevated transaminase more than 1.5 times the upper limits for at least 3 months;<BR/>- ethanol consumption less than 40 g/week;<BR/>- evidence of at least 10% steatosis and necroinflammation on liver biopsy taken within the previous 6 months.</P>
<P>Exclusion criteria:<BR/>- treatment with bile acids in the previous 3 months;<BR/>- anticipated need for transplantation within 1 year or recurrent variceal bleeding, spontaneous portosystemic encephalopathy, diuretic-resistant ascites, or bacterial peritonitis;<BR/>- pregnancy or lactation;<BR/>- treatment with any drugs causing steatosis in the 6 months prior to the study;<BR/>- any other liver diseases;<BR/>- age less than 18 or more than 75 years.</P>
<P>Characteristics of included patients:<BR/>- median age = 47 years<BR/>- males = 44%.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>UDCA 13 mg/kg/day to 15 mg/kg/day <BR/>versus<BR/>placebo for 2 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes were assessed differently:<BR/>- AST, ALT, alkaline phosphatases, bilirubin and albumin every 3 months;<BR/>- history and physical examination and liver enzymes were re-evaluated at 1 and 2 years<BR/>- liver biopsy was performed following 2 years of drug therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Pre- and posttreatment liver biopsies were available in 107 patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-M_x00e8_ndez_x002d_Sanchez-2004">
<CHAR_METHODS>
<P>Generation of allocation sequence: adequate, table of random numbers.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: adequate, double blinding.</P>
<P>Follow-up: adequate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>- BMI &gt;30 kg/m2;<BR/>- age between 20 and 60 years;<BR/>- normal serum, calcium, and potassium levels;<BR/>- negative serum pregnancy test (only in women in childbearing age);<BR/>- presence of hepatic steatosis on US.</P>
<P>Exclusion criteria:<BR/>- history of hypothyroidism or Cushing syndrome;<BR/>- eating disorder or other psychological problem that would interfere with participation in the diet program;<BR/>- use of oral bile acid preparations, aluminium-based antiacids or lithium;<BR/>- long term use of NSAIDs (including aspirin) or antihyperlipidemic drugs (including cholestyramine) within two weeks from entering the trial;<BR/>- diuretic therapy during the trial (it had to be discontinued one day prior to the beginning of the trial).</P>
<P>Characteristic of included patients:<BR/>- mean age: 39 years;<BR/>- female 100%.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>UDCA 1200 mg/day plus a 1200 kcal/day diet<BR/>versus <BR/>placebo plus a 1200 kcal/day diet for 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>US steatosis index, BMI, AST, ALT, glucose, and cholesterol levels were assessed at six weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>We wrote to the authors, but we have not obtained a reply yet.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Santos-2003">
<CHAR_METHODS>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: adequate, double blind.</P>
<P>Follow-up: adequate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>- elevated transaminase or gamma-glutamyltranspeptidase levels at least &gt;=1.5 times the upper limit of normal for more than six months;<BR/>- BMI &gt;25 kg/mq;<BR/>- presence of hepatic steatosis on US. </P>
<P>Exclusion criteria:<BR/>- ethanol consumption more than 40 g/week;<BR/>- decompensated diabetes mellitus;<BR/>- serum cholesterol and triglycerides levels above 300 mg/dl;<BR/>- continuous intake of hepatotoxic drugs;<BR/>- HBsAg positivity and anti-hepatitis C virus antibodies positivity or other concomitant hepatic or recognised systemic diseases.</P>
<P>Characteristic of included patients:<BR/>- mean age = 37 years;<BR/>- male = 93%.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>UDCA 10 mg/kg/day<BR/>versus <BR/>placebo for 3 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes:<BR/>- AST, ALT, and GGT were assessed monthly during the three-month trial;<BR/>- hepatic steatosis indexes, as assessed by computer tomography, magnetic resonance imaging, and histology, were evaluated at the end of the trial.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>We wrote to the authors, but we have not obtained a reply yet.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BMI = body mass index</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bernal_x002d_Reyes-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is not a randomised clinical trial. This study compared the usage of UDCA and alpha-tocopherol in patients with NASH. Sample size was small: 3 compared to 6 patients, respectively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ceriani-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>The authors compared the effect of a six-month treatment with a low-fat diet plus UDCA versus a low-fat diet alone in 31 patients with NASH. The methodology was unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cicek-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study, published in abstract form, compared the use of UDCA and gemfibrozil in patients with NASH. The methodology was unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guma-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study (published as an abstract) compared the use of UDCA and a low-fat diet in patients with NASH. The methodology was unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kiyici-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prospective study, using atorvastatin in hyperlipidemic NASH patients and UDCA in normolipidemic NASH patients.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Laurin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study in which patients were assigned to treatment groups according to the presence of gallstones and triglyceride level. Patients with gallstone disease were given UDCA because of UDCA&#8217;s known beneficial effects in treating gallstones (n = 24), whereas patients with hypertriglyceridemia were placed on clofibrate, because of this agent&#8217;s lipid-lowering effects (n = 16).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tuncer-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study, published in abstract form, compared the use of UDCA and pentoxifylline in NAFLD patients in order to evaluate the effect of treatment on IL-1beta, IL-6, IL-8 and TNF-alpha levels. Moreover, the methodology was unclear and the investigated variables were not included in the types of outcome measures of our review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vajro-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study evaluating treatment of liver abnormalities in four groups of obese children. The four groups included: diet alone (n = 11), UDCA alone (n = 7), UDCA plus diet (n = 7), and untreated control patients (n = 6).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Holoman-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lindor-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-M_x00e8_ndez_x002d_Sanchez-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Santos-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-16 17:44:18 +0100" MODIFIED_BY="dimitrinka nikolova"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Bile acids versus placebo/no intervention - Mortality</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="81.29310195703565" CI_START="0.13106501197242532" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.2641509433962264" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.9100536955437144" LOG_CI_START="-0.8825132284877019" LOG_EFFECT_SIZE="0.5137702335280063" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.4707990243499208" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="141" WEIGHT="100.0" Z="0.7211796038821071">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="19" O_E="0.0" SE="0.0" STUDY_ID="STD-Ers_x00f6_z-2005" TOTAL_1="29" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="81.29310195703565" CI_START="0.13106501197242532" EFFECT_SIZE="3.2641509433962264" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9100536955437144" LOG_CI_START="-0.8825132284877019" LOG_EFFECT_SIZE="0.5137702335280063" ORDER="20" O_E="0.0" SE="1.6403676346052694" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" VAR="2.6908059766604864" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21" O_E="0.0" SE="0.0" STUDY_ID="STD-M_x00e8_ndez_x002d_Sanchez-2004" TOTAL_1="14" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="22" O_E="0.0" SE="0.0" STUDY_ID="STD-Santos-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="141" WEIGHT="0.0" Z="0.0">
<NAME>Liver-related mortality</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23" O_E="0.0" SE="0.0" STUDY_ID="STD-Ers_x00f6_z-2005" TOTAL_1="29" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24" O_E="0.0" SE="0.0" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25" O_E="0.0" SE="0.0" STUDY_ID="STD-M_x00e8_ndez_x002d_Sanchez-2004" TOTAL_1="14" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="26" O_E="0.0" SE="0.0" STUDY_ID="STD-Santos-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Bile acids versus placebo/no intervention - Radiological response</NAME>
<CONT_OUTCOME CHI2="12.274705978550648" CI_END="0.1643522780083792" CI_START="-0.6007737129032951" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2182107174474579" ESTIMABLE="YES" I2="83.70633069749381" I2_Q="63.16850162197384" ID="CMP-002.01" NO="1" P_CHI2="0.002160644378146559" P_Q="0.09940484368688718" P_Z="0.2635896545914612" Q="2.7150673853567806" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="55" UNITS="" WEIGHT="100.0" Z="1.1179469847261672">
<NAME>Fatty infiltration</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0148516265446936" CI_START="-0.4254209018244385" DF="0.0" EFFECT_SIZE="0.2947153623601275" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="0.4224869310055951" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="28.221270130329636" Z="0.8021141617838016">
<NAME>CT examination</NAME>
<CONT_DATA CI_END="1.0148516265446936" CI_START="-0.4254209018244385" EFFECT_SIZE="0.2947153623601275" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="-0.5" ORDER="27" SD_1="4.15" SD_2="5.05" SE="0.36742321280641327" STUDY_ID="STD-Santos-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="28.221270130329636"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.559638593193867" CI_END="0.03167114089455847" CI_START="-0.8714272539434099" DF="1.0" EFFECT_SIZE="-0.4198780565244257" ESTIMABLE="YES" I2="89.5393534990751" ID="CMP-002.01.02" NO="2" P_CHI2="0.0019890407044249603" P_Z="0.06838000768623133" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="40" WEIGHT="71.77872986967036" Z="1.822494366927091">
<NAME>US examination</NAME>
<CONT_DATA CI_END="0.5241567989481922" CI_START="-0.5241567989481922" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="28" SD_1="0.62" SD_2="0.57" SE="0.26743185236191797" STUDY_ID="STD-Ers_x00f6_z-2005" TOTAL_1="29" TOTAL_2="27" WEIGHT="53.27009503851214"/>
<CONT_DATA CI_END="-0.7391046111195403" CI_START="-2.5175714076576874" EFFECT_SIZE="-1.6283380093886137" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-0.1" ORDER="29" SD_1="0.67" SD_2="0.76" SE="0.4536988461437215" STUDY_ID="STD-M_x00e8_ndez_x002d_Sanchez-2004" TOTAL_1="14" TOTAL_2="13" WEIGHT="18.50863483115822"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Bile acids versus placebo/no intervention - Histological response</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.09792409238371075" CI_START="-0.2979240923837108" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3220468513125465" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="86" UNITS="" WEIGHT="100.0" Z="0.990260438198862">
<NAME>Overall steatosis difference</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.09792409238371075" CI_START="-0.2979240923837108" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.3" ORDER="30" SD_1="0.6" SD_2="0.7" SE="0.10098353538376764" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3597736920583451" CI_START="-0.15977369205834505" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.45055564188317987" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="86" UNITS="" WEIGHT="100.0" Z="0.7544890204277682">
<NAME>Overall inflammation difference</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3597736920583451" CI_START="-0.15977369205834505" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.1" ORDER="31" SD_1="0.9" SD_2="0.8" SE="0.13254003344316873" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2767775926349032" CI_START="-0.2767775926349032" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="86" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Overall fibrosis difference</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2767775926349032" CI_START="-0.2767775926349032" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="32" SD_1="1.0" SD_2="0.8" SE="0.14121565233753758" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4906757762037235" CI_START="0.6262920336795564" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2489557226399333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.396317196918237" LOG_CI_START="-0.20322311241016144" LOG_EFFECT_SIZE="0.09654704225403782" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.5278796608092056" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0" Z="0.6312460486393445">
<NAME>Improvement in steatosis</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4906757762037235" CI_START="0.6262920336795565" EFFECT_SIZE="1.2489557226399333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.396317196918237" LOG_CI_START="-0.20322311241016136" LOG_EFFECT_SIZE="0.09654704225403782" ORDER="33" O_E="0.0" SE="0.352172945471896" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" VAR="0.12402578352235102" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.769290222018975" CI_START="0.2863704880597068" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7118093174431203" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.2477990773886898" LOG_CI_START="-0.5430717403209523" LOG_EFFECT_SIZE="-0.14763633146613125" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.4643180407094085" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0" Z="0.7317551387753196">
<NAME>Improvement in inflammation</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7692902220189746" CI_START="0.2863704880597068" EFFECT_SIZE="0.7118093174431203" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.24779907738868973" LOG_CI_START="-0.5430717403209523" LOG_EFFECT_SIZE="-0.14763633146613125" ORDER="34" O_E="0.0" SE="0.46456143319632964" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" VAR="0.21581732521342786" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.838015499816425E-32" CI_END="2.1680656119932995" CI_START="0.3579583077248989" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8809523809523808" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="100.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.3360724210838136" LOG_CI_START="-0.44616755374562456" LOG_EFFECT_SIZE="-0.05504756633090553" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.7826617099202996" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0" Z="0.2758520426386531">
<NAME>Improvement in fibrosis</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1680656119933" CI_START="0.3579583077248989" EFFECT_SIZE="0.8809523809523809" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.33607242108381363" LOG_CI_START="-0.44616755374562456" LOG_EFFECT_SIZE="-0.05504756633090548" ORDER="35" O_E="0.0" SE="0.45949163336513665" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" VAR="0.21113256113256115" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Bile acids versus placebo/no intervention - Biochemical response</NAME>
<CONT_OUTCOME CHI2="60.64934017535231" CI_END="0.7153820203124197" CI_START="-5.36508405575867" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3248510177231254" ESTIMABLE="YES" I2="96.70235489088999" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="6.7390537594747E-14" P_Q="1.0" P_Z="0.13393209827128946" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="126" UNITS="" WEIGHT="100.0" Z="1.4987746686362216">
<NAME>AST improvement</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-30.49035212771674" CI_START="-50.70964787228326" EFFECT_SIZE="-40.6" ESTIMABLE="YES" MEAN_1="-20.1" MEAN_2="20.5" ORDER="36" SD_1="22.55" SD_2="15.65" SE="5.158078389208615" STUDY_ID="STD-Ers_x00f6_z-2005" TOTAL_1="29" TOTAL_2="27" WEIGHT="9.043607186634173"/>
<CONT_DATA CI_END="13.88610927880492" CI_START="-15.88610927880492" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-21.7" MEAN_2="-20.7" ORDER="37" SD_1="53.2" SD_2="43.8" SE="7.5950932752972244" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" WEIGHT="4.171107113980968"/>
<CONT_DATA CI_END="4.863501565754612" CI_START="-1.6635015657546117" EFFECT_SIZE="1.6000000000000005" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-8.3" ORDER="38" SD_1="4.89" SD_2="3.72" SE="1.6650824155426813" STUDY_ID="STD-M_x00e8_ndez_x002d_Sanchez-2004" TOTAL_1="14" TOTAL_2="13" WEIGHT="86.78528569938486"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.384645296009655" CI_END="2.0425781121213697" CI_START="-4.13228604298145" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0448539654300402" ESTIMABLE="YES" I2="31.579414126606373" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.22281358247946015" P_Q="1.0" P_Z="0.5071420818304468" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="141" UNITS="" WEIGHT="100.0" Z="0.6632943138204593">
<NAME>ALT improvement</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.994416098566205" CI_START="-12.594416098566214" EFFECT_SIZE="8.199999999999996" ESTIMABLE="YES" MEAN_1="-44.6" MEAN_2="-52.8" ORDER="39" SD_1="46.45" SD_2="32.1" SE="10.609590922379141" STUDY_ID="STD-Ers_x00f6_z-2005" TOTAL_1="29" TOTAL_2="27" WEIGHT="2.204455640430345"/>
<CONT_DATA CI_END="19.786877663119512" CI_START="-21.986877663119515" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="-32.7" MEAN_2="-31.6" ORDER="40" SD_1="69.8" SD_2="67.3" SE="10.656766056862544" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" WEIGHT="2.184981569537786"/>
<CONT_DATA CI_END="4.2932926071995965" CI_START="-3.093292607199593" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" MEAN_1="-18.9" MEAN_2="-19.5" ORDER="41" SD_1="5.63" SD_2="4.09" SE="1.8843675885535731" STUDY_ID="STD-M_x00e8_ndez_x002d_Sanchez-2004" TOTAL_1="14" TOTAL_2="13" WEIGHT="69.88233224770427"/>
<CONT_DATA CI_END="-0.21315205644591195" CI_START="-12.38684794355409" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" MEAN_1="-29.0" MEAN_2="-22.7" ORDER="42" SD_1="8.52" SD_2="8.49" SE="3.105591731055452" STUDY_ID="STD-Santos-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="25.728230542327605"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5711909020110075" CI_END="11.5084263050789" CI_START="-17.859144160576918" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.175358927749008" ESTIMABLE="YES" I2="36.35401027844075" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.2100341940330518" P_Q="1.0" P_Z="0.6716818296444333" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="113" UNITS="" WEIGHT="100.0" Z="0.42384092641602855">
<NAME>ALP improvement</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.48738948695641" CI_START="-74.68738948695642" EFFECT_SIZE="-30.1" ESTIMABLE="YES" MEAN_1="-38.6" MEAN_2="-8.5" ORDER="43" SD_1="89.95" SD_2="80.25" SE="22.749086125386" STUDY_ID="STD-Ers_x00f6_z-2005" TOTAL_1="29" TOTAL_2="27" WEIGHT="10.845559363407311"/>
<CONT_DATA CI_END="15.651294078347368" CI_START="-15.451294078347368" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="-8.1" MEAN_2="-8.2" ORDER="44" SD_1="54.2" SD_2="47.5" SE="7.93447951136551" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" WEIGHT="89.15444063659268"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.01856380069950986" CI_END="0.7232639328671162" CI_START="-36.543601525306386" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-17.910168796219637" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="0.8916244154441876" P_Q="1.0" P_Z="0.05958023217452486" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="113" UNITS="" WEIGHT="100.0" Z="1.8838872207817845">
<NAME>GGT improvement</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.201367429317127" CI_START="-44.40136742931713" EFFECT_SIZE="-19.1" ESTIMABLE="YES" MEAN_1="-40.6" MEAN_2="-21.5" ORDER="45" SD_1="52.2" SD_2="44.3" SE="12.909098141032736" STUDY_ID="STD-Ers_x00f6_z-2005" TOTAL_1="29" TOTAL_2="27" WEIGHT="54.237261393062916"/>
<CONT_DATA CI_END="11.044625159611801" CI_START="-44.0446251596118" EFFECT_SIZE="-16.5" ESTIMABLE="YES" MEAN_1="-41.5" MEAN_2="-25.0" ORDER="46" SD_1="117.5" SD_2="46.3" SE="14.053638422379334" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" WEIGHT="45.76273860693709"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14283615252872708" CI_START="-0.14283615252872708" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="86" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Bilirubin improvement</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.14283615252872708" CI_START="-0.14283615252872708" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="47" SD_1="0.3" SD_2="0.6" SE="0.072876927155499" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Bile acids versus placebo/no intervention - Adverse events</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.978991567172199" CI_START="0.04727335847883176" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5316455696202531" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.7766279408874249" LOG_CI_START="-1.325383542672507" LOG_EFFECT_SIZE="-0.274377800892541" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6088803225055015" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0" Z="0.5116723786836055">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours UDCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.978991567172199" CI_START="0.04727335847883176" DF="0.0" EFFECT_SIZE="0.5316455696202531" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.7766279408874249" LOG_CI_START="-1.325383542672507" LOG_EFFECT_SIZE="-0.274377800892541" NO="1" P_CHI2="1.0" P_Z="0.6088803225055015" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0" Z="0.5116723786836055">
<NAME>Cardiac arrest</NAME>
<DICH_DATA CI_END="5.978991567172199" CI_START="0.04727335847883176" EFFECT_SIZE="0.5316455696202531" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7766279408874249" LOG_CI_START="-1.325383542672507" LOG_EFFECT_SIZE="-0.274377800892541" ORDER="48" O_E="0.0" SE="1.2347319505677592" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" VAR="1.5245629897528632" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9132338438669074" CI_END="4.933853691450396" CI_START="0.7827721168691392" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.9652183335139235" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.6931862667714996" LOG_CI_START="-0.10636465274518692" LOG_EFFECT_SIZE="0.29341080701315636" METHOD="MH" NO="2" P_CHI2="0.6334229752949405" P_Q="0.0" P_Z="0.1502939285822374" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="189" TOTAL_2="199" WEIGHT="200.0" Z="1.4384940355474558">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>UDCA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8965473365757387" CI_END="6.0936559977991624" CI_START="0.717451203025782" DF="1.0" EFFECT_SIZE="2.090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.7848779335633105" LOG_CI_START="-0.14420763184457472" LOG_EFFECT_SIZE="0.3203351508593678" NO="1" P_CHI2="0.34370930416628676" P_Z="0.17652444073041856" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="113" WEIGHT="100.0" Z="1.3515339857657367">
<NAME>Gastrointestinal intolerance</NAME>
<DICH_DATA CI_END="147.49384197221195" CI_START="0.3577633358983614" EFFECT_SIZE="7.264150943396227" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1687738884272902" LOG_CI_START="-0.44640416861186705" LOG_EFFECT_SIZE="0.8611848599077117" ORDER="49" O_E="0.0" SE="1.5361685360449633" STUDY_ID="STD-Ers_x00f6_z-2005" TOTAL_1="29" TOTAL_2="27" VAR="2.3598137711345255" WEIGHT="9.411840219088985"/>
<DICH_DATA CI_END="5.108420894573062" CI_START="0.47238240866154574" EFFECT_SIZE="1.5534246575342465" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7082866725890288" LOG_CI_START="-0.32570628371616506" LOG_EFFECT_SIZE="0.19129019443643186" ORDER="50" O_E="0.0" SE="0.6073725808813523" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" VAR="0.36890145200647484" WEIGHT="90.58815978091101"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.056264160280769" CI_START="0.26627044673202604" DF="0.0" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="1.0024366729759793" LOG_CI_START="-0.5746770330858173" LOG_EFFECT_SIZE="0.21387981994508104" NO="2" P_CHI2="1.0" P_Z="0.5950031363739208" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0" Z="0.5315998998690394">
<NAME>Miscellaneous</NAME>
<DICH_DATA CI_END="10.056264160280769" CI_START="0.26627044673202604" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0024366729759793" LOG_CI_START="-0.5746770330858173" LOG_EFFECT_SIZE="0.21387981994508104" ORDER="51" O_E="0.0" SE="0.9264043977794515" STUDY_ID="STD-Lindor-2004" TOTAL_1="80" TOTAL_2="86" VAR="0.8582251082251082" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-16 17:44:23 +0100" MODIFIED_BY="dimitrinka nikolova">
<APPENDIX ID="APP-01" MODIFIED="2008-10-16 17:44:23 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<TITLE MODIFIED="2008-10-16 17:43:54 +0100" MODIFIED_BY="dimitrinka nikolova">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-16 17:44:23 +0100" MODIFIED_BY="dimitrinka nikolova">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>June 2006</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>bile acid*<BR/>bile acid* and steatohepatitis<BR/>non alcoholic fatty liver disease<BR/>bile acid*<BR/>bile acid* and steatohepatitis<BR/>non alcoholic fatty liver disease<BR/>UDCA<BR/>ursodeoxycholic acid<BR/>ursodiol<BR/>taurodeoxycholic acid</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 2, 2006</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>bile acid*<BR/>bile acid* and steatohepatitis<BR/>non alcoholic fatty liver disease<BR/>UDCA<BR/>ursodeoxycholic acid<BR/>ursodiol<BR/>taurodeoxycholic acid</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (WinSPIRS 5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1950 to June 2006</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>("bile acid*" OR "bile salt*" OR "ursodeoxycholic acid" OR UDCA OR urso OR ursodiol OR "*cholic acid" OR *cholate OR tauro* OR taurine OR "taurine conjugate*" OR TUDCA OR glycine OR "cholanic acid") AND ("non*alcoholic fatty liver" OR "non alcoholic fatty liver" OR "nonalcoholic fatty liver" OR "NAFL*" OR "NASH" OR (non*alcoholic AND steato*hepatitis) OR (non alcoholic AND steato*hepatitis) OR (nonalcoholic AND steato*hepatitis))</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (WinSPIRS 5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to June 2006</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>("bile acid*" OR "bile salt*" OR "ursodeoxycholic acid" OR UDCA OR urso OR ursodiol OR "*cholic acid" OR *cholate OR tauro* OR taurine OR "taurine conjugate*" OR TUDCA OR glycine OR "cholanic acid") AND ("non*alcoholic fatty liver" OR "non alcoholic fatty liver" OR "nonalcoholic fatty liver" OR "NAFL*" OR "NASH" OR (non*alcoholic AND steato*hepatitis) OR (non alcoholic AND steato*hepatitis) OR (nonalcoholic AND steato*hepatitis)) AND (trial* OR studies OR random* OR allocat* OR double*bind* OR placebo)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Chinese Biomedical Database</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(1978 to July 2005)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Performed by Maoling Wei from The Chinese Cochrane Centre. The search strategy can be provided at a request.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>